Comparing the efficacy of four different protocols for eradicating of helicobacter pylori infection in Ahvaz, southwest Iran

Masjedizadeh, Abdolrahim; Zaeemzadeh, Narjes; Mard, Seyyed Ali; Vanani, Ghazal Salehi

doi:10.5114/pg.2015.49001

Cited by 6 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar finding of gastrointestinal dominance have been reported in other studies elsewhere[23,30,31]. Self-reported ADEs in the present study was comparable 19%[32], higher than 10% -18% [33–36] and lower than 36%-76% [37–40] reported previously. The variability could be due to different factors such as duration of triple therapy, socio-demographic differences of patients, duration and severity of the disease, pharmacogenetic variability among patients, and drug combinations and possible interactions among these factors.…”

Section: Discussionsupporting

confidence: 92%

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study

Gebeyehu¹,

Nigatu²,

Engidawork³

2019

PLoS ONE

View full text Add to dashboard Cite

BackgroundOne of the most common reasons for poor medication adherence and associated treatment failure of triple therapy is adverse drug effect (ADEs) of medications.ObjectiveAssessment of ADEs and associated factors during H. pylori eradication therapy.MethodConsented H. pylori positive adult outpatients on standard triple therapy (proton pump inhibitor, amoxicillin and clarithromycin) were involved in this facility based follow up study from May 2016 to April 2018 at Bahir Dar city in Ethiopia. Pre-developed questionnaire and formats were used to collect sociodemographic, medical information, and patient practice data before, during, and after therapy. Bivariate and backward stepwise multivariate logistic regression was used to analyze data. P-value < 0.05 at 95%CI was considered as significant.ResultA total of 421 patients were involved in the study. Almost 80% of the patients were urban residents. Mean (±SD) age and body weight of patients were 30.63 (± 10.74) years and 56.79 (± 10.17) kg, respectively. ADE was reported from 26.1% of the patients and of all the reported ADEs, more than 85% was manifested with gastrointestinal symptoms which include gastrointestinal discomfort(39.1%), nausea (13.6%), constipation(12.7%), diarrhea(12.9%) and anorexia(10%). Determinants of self-reported ADEs among patients in the present study were body mass index above 25 (AOR: 2.55; 95%CI (1.21–5.38), p = 0.014), duration of acid-pepsin disorder more than 3weeks (AOR: 3.57; 95%CI (1.63–7.81), p = 0.001), pain feeling during long interval between meals (AOR: 2.14; 95%CI (1.19–3.84), p = 0.011), and residence in urban area (AOR: 1.95; 95% CI (1.04–3.67), p = 0.038).ConclusionSignificant proportion of patients reported ADEs which commonly manifested with gastrointestinal symptoms. Consideration of patients’ body mass index, duration of the disorder, period of the day when patients feel pain, and patients’ area of residence could help to reduce ADEs experienced during H. pylori eradication therapy.

show abstract

Section: Discussionsupporting

confidence: 92%

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study

Gebeyehu¹,

Nigatu²,

Engidawork³

2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Among these studies, those with higher doses of furazolidone (200 mg three times a day vs. 200 mg twice a day or daily) could achieve optimal eradication rates. 30 , 38 , 39…”

Section: Introductionmentioning

confidence: 99%

Eradication of Helicobacter Pylori in Iran: A Review

Fakheri

Firoozi²,

Bari

2017

Middle East J Dig Dis

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) infection is one of the most common bacterial infections, affecting almost half of the world’s population. It is associated with peptic ulcer disease, gastric adenocarcinoma, and lymphoma. In Iran, the prevalence of H. pylori infection has been reported to be between 36% and 90% in different geographic regions. Several studies have assessed the efficacy of different therapeutic options for firstline and second-line H. pylori eradication in Iran; however, the results are conflicting. Therefore, we conducted a review to evaluate different studies in order to select the best options and to provide recommendations for H. pylori eradication in Iran. Accordingly, we searched through PubMed to obtain relevant randomized clinical trials published in English language up to June 2017. According to our study, among first-line eradication regimens, bismuth-based furazolidone- or clarithromycin-containing quadruple therapies, hybrid regimen, and concomitant therapy seem to be appropriate options. Also, 10- or 14-day clarithromycin-containing triple therapy can be used if local H. pylori resistance to clarithromycin is known to be less than 15%. For second-line H. pylori eradication, bismuth-based quadruple therapies and 14-day levofloxacin-based triple therapy can be used, provided that antibiotics other than those used in the first-line regimen are used. Third-line H. pylori eradication regimens have not been addressed in Iranian studies. However, most guidelines recommend treatment according to the results of culture and susceptibility testing. Although we limited our investigation to H. pylori eradication regimens in Iran, the results are transferrable to any region as long as the patterns of antibiotic resistance are the same.

show abstract

“…In the same year another finding showed that eradication was possible by 95% after a 10-days treatment. Studies were also carried out in Taiwan, which is country rich in H. pylori cases, that an accepted treatment was found after 7, days, 10 days and 14 days 18 . As per Maastricht V Consensus findings the concomitant treatment is the most effective and accepted treatment and this treatment is accepted when the resistance to the metronidazole and clarithromycin is less than 15%.…”

Section: Discussionmentioning

confidence: 99%

A Comparison Between 10-Day and 12-Day Concomitant Regimens for Helicobacter Pylori Eradication

Rubina¹,

Butt²,

Shah³

2022

PJMHS

View full text Add to dashboard Cite

H. pylori (Helicobacter pylori) is the most prevalent infection worldwide which leads to gastric ulcer and cancer. In our research work, patients infected with H. pylori were given concomitant treatment for 10 and 12 days and compared to find the efficiency of treatment. Objective: The objective of this study is to find a cost-effective therapeutic method for the treatment of H. pylori. Previous 14-day treatment was effective but it was expensive due to the high cost of antibiotics as well as the negative side effects of the treatment, so an alternative method is required to reduce the need of costly antibiotics and the duration of treatment. Study design: It is a comparative study with statistical approach, conducted in the medicine department of Sialkot Medical College, Sialkot for the duration of six months from June 2021 to November 2021. Methods: For this study, 196 patients with gastric ulcers were selected and confirmed H. pylori positive by a diagnostic test. These patients randomly distributed into two groups and given treatment for 10 and 12 days respectively. UBT was used to find either H. pylori is eradicated or not. “Registry of clinical trials” registered this experiment. Results: For this research work, 196 patients were selected, after the concomitant therapy eradication rate was analyzed that comes out as 83 % (CI 95.0%: 76-90) and 88 % (CI 95%: 82-94) for 10 and 12 day therapy, respectively (p = 0.23). Then, prediction of per-protocol eradication was done and it came out as 85% (CI 95%: 79-92) and 92% (CI 95%: 87-97), respectively (p = 0.18). When side effects were compared between two groups, no statistical difference exist between two (3.5% vs. 8.0%; p = 0.419). Conclusion: All the results suggested that the concomitant therapy that was given for 12 days was more effective for treatment and per-protocol assessment. For the reduction of the cost of antibiotics, 12 day treatment is more effective for treatment as well as the replacement of 14 day treatment that was suggested by international rules. Keywords: Helicobacter pylori, gastric ulcer, concomitant therapy, treatment efficacy, H. pylori eradication.

show abstract

Comparing the efficacy of four different protocols for eradicating of helicobacter pylori infection in Ahvaz, southwest Iran

Cited by 6 publications

References 26 publications

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study

Eradication of Helicobacter Pylori in Iran: A Review

A Comparison Between 10-Day and 12-Day Concomitant Regimens for Helicobacter Pylori Eradication

Contact Info

Product

Resources

About